Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: To determine the safety and efficacy of neoadjuvant toripalimab combined with chemotherapy in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
Patients And Methods: This single-arm investigator-initiated trial was conducted at a tertiary cancer hospital in China. The untreated LA-HNSCC patients received two cycles of neoadjuvant paclitaxel and cisplatin (TP) + toripalimab regimen (paclitaxel 175 mg/m d1, cisplatin 75 mg/m d1, and toripalimab 240 mg d1, every 3 weeks). Surgery or chemoradiotherapy (CRT) was determined via the patient-doctor consensus. The primary endpoints were objective response rate (ORR) and safety.
Results: The study enrolled a total of 23 patients. All the patients completed the entire treatment course with an ORR of 78.3% (18/23). Any grades of treatment-related adverse events (TRAEs) were reported in 12 patients (52.2%), and three patients experienced grade 3-4- TRAEs. No delay for curative treatment was observed. Twelve patients underwent radical surgery, and six patients developed pathological complete response (pCR), with a pCR rate of 50%. With a median follow-up of 15 months, 12 surgery patients maintained event-free survival; however, three out of 11 who received CRT suffered from local recurrence or metastases.
Conclusions: Neoadjuvant TP + toripalimab for LA-HNSCC showed high ORR and pCR rates with a good safety profile.
Clinical Trial Registration: https://www.chictr.org.cn/showproj.html?proj=231832, identifier ChiCTR2400091148.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12127343 | PMC |
| http://dx.doi.org/10.3389/fonc.2025.1571776 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of neoadjuvant toripalimab plus chemotherapy in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma (NICE): a multicentre, single-arm, exploratory phase 2 study.
EClinicalMedicine
September 2025
Department of General Surgery, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, Guangdong, China.
Background: In locally advanced gastric or gastroesophageal junction adenocarcinoma (GC/EGJC), deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) tumors exhibit high responsiveness to immunotherapy. The synergistic efficacy of neoadjuvant immunotherapy combined with chemotherapy in dMMR/MSI-H GC/EGJC remains uncertain.
Methods: The NICE trial is a multicentre, single-arm, exploratory phase 2 study conducted at six hospitals in China, evaluating the safety and efficacy of toripalimab in combination with CapeOX as perioperative therapy for locally advanced GC/EGJC across three biomarker-defined cohorts.
Toripalimab, bevacizumab, and irinotecan in dMMR/MSI locally advanced colorectal cancer: First-stage results from a phase 1b/2 trial.
Cell Rep Med
August 2025
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China; Key Laboratory of Carcinogenesis an
This is the first stage of the phase 1b/2 trial evaluating the effectiveness and safety of toripalimab, irinotecan, and bevacizumab in patients with rectal cancer refusing up-front surgery or radiation therapy (rectum cohort) and patients with T4NanyM0 colon cancer (colon cohort) with deficiency of mismatch repair (dMMR) or microsatellite instability (MSI). This trial allows a doctor-patient shared decision-making process to determine whether to omit irinotecan or bevacizumab and the optimal surgery timing. The primary endpoint pathological complete response (pCR) rates in the full analysis set (FAS) and per-protocol set (PPS) are 57.
View Article and Find Full Text PDFFirst case report of immune checkpoint inhibitor therapy to treat secretory carcinoma.
Ther Adv Med Oncol
July 2025
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 113 Baohe Avenue, Longgang District, Shenzhen, 518116, Guangdong Province, China.
Secretory carcinoma (SC) is a newly defined and exceedingly rare pathologic subtype of lung cancer. We present a case of SC that was initially misdiagnosed as stage IIIB (cT2aN3M0) invasive mucinous adenocarcinoma harboring a programmed cell death ligand 1 tumor proportion score of 10% and an - fusion gene. The patient received five cycles of toripalimab and pemetrexed plus carboplatin at a local hospital without treatment-related adverse events.
View Article and Find Full Text PDFNetwork meta-analysis of perioperative immunotherapies in non-small-cell lung cancer according to tumor programmed death ligand 1 expression.
Farm Hosp
July 2025
Servicios Centrales de Extremadura, Subdirección de Farmacia, Mérida, España.
Objective: Immunotherapy has emerged as a therapeutic alternative to chemotherapy (CT) for perioperative treatment of resectable non-small cell lung cancer (NSCLC). The objective is to perform a network meta-analysis comparing the perioperative efficacy of immunotherapies in resectable NSCLC taking into account tumor expression of programmed death ligand 1 (PD-L1).
Method: A review was performed in Pubmed® and EMBASE® until September 17, 2024.
Toripalimab treatment of bladder-preserving therapy for locally advanced bladder cancer: a case report.
Front Oncol
June 2025
Department of Urology, West China Hospital, Sichuan University, Chendu, China.
Neoadjuvant chemotherapy and radical cystectomy is the standard treatment for muscle invasive bladder cancer. For patients who are intolerant or unwilling to receive radical surgery and chemotherapy, the use of immune therapy combined with bladder preservation treatment has gradually become a viable treatment option. In this article, We aimed to present a case of cT2N0M0 Bladder cancer patient who was intolerant to chemotherapy and was treated with Toripalimab as a single-agent bladder preservation therapy for three cycles.
View Article and Find Full Text PDF